Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Verzenios ® ▼ (abemaciclib)
Verzenios® ▼ (abemaciclib): Use in Patients with COVID-19
The use of Verzenios (abemaciclib) in patients with COVID-19 has not been studied.
COVID-19 is an infectious respiratory disease caused by SARS-CoV-2, previously referred to as "2019 novel coronavirus."1
Treating physicians should assess the patient’s individual benefit/risk ratio considering the patient's signs and symptoms, prior medical history, concomitant medications, and other individual factors when making abemaciclib treatment decisions in the context of COVID-19. Adverse reactions of abemaciclib to be considered in particular, in the context of COVID-19, include ILD/pneumonitis and neutropenia (see below for further information). Abemaciclib dose adjustments, made at the physician’s discretion, should follow the label. Supportive treatment should be provided as clinically indicated and patients monitored appropriately. Drug interactions between abemaciclib and potential COVID-19 treatments should be considered and are described below.2
ILD-Related Warnings and Precautions
Interstitial lung disease and/or pneumonitis was reported in patients receiving abemaciclib. Monitor patients for pulmonary symptoms indicative of ILD/pneumonitis and treat as medically appropriate.3 Symptoms may include hypoxia, cough, dyspnea, or interstitial infiltrates on radiologic exams. Infectious, neoplastic, and other causes for such symptoms should be excluded by means of appropriate investigations.2 Based on the severity of ILD/pneumonitis, abemaciclib may require dose modification.2
Neutropenia-Related Warnings and Precautions
Neutropenia was reported in patients receiving abemaciclib. 3
Complete blood counts should be monitored prior to the start of Abemaciclib therapy, every two weeks for the first two months, monthly for the next two months, and as clinically indicated. 3
Dose modification is recommended for patients who develop Grade 3 or 4 neutropenia.3
Hydroxychloroquine or chloroquine are not expected to have a clinically relevant effect on abemaciclib exposure.2
Remdesivir, favipiravir or azithromycin are not expected to have a clinically relevant effect on abemaciclib exposure. 2
The combination of lopinavir/ritonavir is a strong CYP3A inhibitor.2 With concomitant use of strong CYP3A inhibitors other than ketoconazole, in patients with recommended starting doses of 200 mg twice daily or 150 mg twice daily, reduce the abemaciclib dose to 100 mg twice daily. In patients who have had a dose reduction to 100 mg twice daily due to adverse reactions, further reduce the abemaciclib dose to 50 mg twice daily.4
Infectious Disease Resources
For the most current information regarding COVID-19, please refer to the following resources:
Coronavirus disease (COVID-19) outbreak on the regional office of the EU WHO
COVID-19 on the ECDC web page.
European Society for Medical Oncology (ESMO)
1. Naming the coronavirus disease (COVID-19) and the virus that causes it. World Health Organization. Accessed March 17, 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it
5. Coronavirus disease (COVID-19) outbreak. World Health Organization Europe. Accessed March 20, 2020. http://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/novel-coronavirus-2019-ncov
6. COVID-19. European Centre for Disease Prevention and Control. Accessed March 20, 2020. https://www.ecdc.europa.eu/en/novel-coronavirus-china
7. European Society for Medical Oncology. Accessed March 23th. https://www.esmo.org/newsroom/covid-19-and-cancer/covid-19-useful-resources
8. [NICE] National Institute for Health and Care Excellence. Coronavirus (COVID-19). Available from: https://www.nice.org.uk/covid-19. Accessed 25 March 2020.
COVID-19 = coronavirus disease 2019
ILD = interstitial lung disease
Lilly = Eli Lilly and Company
ECDC = European Centre for Disease Prevention and Control
ESMO = European Society for Medical Oncology
EU WHO = World Health Organization (European regional office)
SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2
WHO = World Health Organization
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Date of Last Review: May 25, 2020